Fusion pore regulation by cAMP/Epac2 controls cargo release during insulin exocytosis
Abstract
Regulated exocytosis establishes a narrow fusion pore as initial aqueous connection to the extracellular space, through which small transmitter molecules such as ATP can exit. Co-release of polypeptides and hormones like insulin requires further expansion of the pore. There is evidence that pore expansion is regulated and can fail in diabetes and neurodegenerative disease. Here we report that the cAMP-sensor Epac2 (Rap-GEF4) controls fusion pore behavior by acutely recruiting two pore-restricting proteins, amisyn and dynamin-1, to the exocytosis site in insulin-secreting beta-cells. cAMP elevation restricts and slows fusion pore expansion and peptide release, but not when Epac2 is inactivated pharmacologically or in Epac2-/- (Rapgef4-/-) mice. Consistently, overexpression of Epac2 impedes pore expansion. Widely used antidiabetic drugs (GLP-1 receptor agonists and sulfonylureas) activate this pathway and thereby paradoxically restrict hormone release. We conclude that Epac2/cAMP controls fusion pore expansion and thus the balance of hormone and transmitter release during insulin granule exocytosis.
Data availability
Source data file has been provided for Fig 7. All raw data are available on the Dryad Digital Repository (https://doi.org/10.5061/dryad.6b604g8).
-
Data from: Fusion pore regulation by cAMP/Epac2 controls cargo release during insulin exocytosisDryad Digital Repository, doi:10.5061/dryad.6b604g8.
Article and author information
Author details
Funding
Swedish Research Council (2014-02575)
- Anders Tengholm
- Sebastian Barg
Norwegian Research Council
- Marit Bakke
Helse-Bergen
- Marit Bakke
Olga Jönssons stipend
- Alenka Guček
P O Zetterlingsstiftelse
- Alenka Guček
Swedish Research Council (2017-00956)
- Anders Tengholm
- Sebastian Barg
Swedich Research Council (2018-02871)
- Anders Tengholm
- Sebastian Barg
European Foundation for the Study of Diabetes
- Anders Tengholm
- Sebastian Barg
Diabetes Wellness Network Sweden
- Anders Tengholm
- Sebastian Barg
Swedish Diabetes Society
- Anders Tengholm
- Sebastian Barg
Swedish Society for Medical Research
- Nikhil R Gandasi
Hjärnfonden
- Sebastian Barg
NovoNordisk
- Nikhil R Gandasi
- Anders Tengholm
- Sebastian Barg
Family Ernfors Foundation
- Alenka Guček
- Anders Tengholm
- Sebastian Barg
European Foundation for the Study of Diabetes
- Nikhil R Gandasi
- Anders Tengholm
- Sebastian Barg
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Axel T Brunger, Stanford University, United States
Ethics
Animal experimentation: This study was performed in strict accordance with European and Swedish legislation, fundamental ethical principles and approved by the Regional Ethics Board Uppsala (license number 31, 1-32).
Version history
- Received: September 5, 2018
- Accepted: April 28, 2019
- Accepted Manuscript published: May 17, 2019 (version 1)
- Accepted Manuscript updated: May 20, 2019 (version 2)
- Version of Record published: June 10, 2019 (version 3)
Copyright
© 2019, Guček et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,143
- views
-
- 387
- downloads
-
- 40
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cell Biology
A new protocol can customize the flavor of lab-grown meat by controlling the level of fat deposited between muscle cells.
-
- Cancer Biology
- Cell Biology
Alterations in the function of K+ channels such as the voltage- and Ca2+-activated K+ channel of large conductance (BKCa) reportedly promote breast cancer (BC) development and progression. Underlying molecular mechanisms remain, however, elusive. Here, we provide electrophysiological evidence for a BKCa splice variant localized to the inner mitochondrial membrane of murine and human BC cells (mitoBKCa). Through a combination of genetic knockdown and knockout along with a cell permeable BKCa channel blocker, we show that mitoBKCa modulates overall cellular and mitochondrial energy production, and mediates the metabolic rewiring referred to as the ‘Warburg effect’, thereby promoting BC cell proliferation in the presence and absence of oxygen. Additionally, we detect mitoBKCa and BKCa transcripts in low or high abundance, respectively, in clinical BC specimens. Together, our results emphasize, that targeting mitoBKCa could represent a treatment strategy for selected BC patients in future.